{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:52:47Z","timestamp":1795175567766,"version":"4.10.3"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41579-022-00777-y","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T10:04:27Z","timestamp":1661162667000},"page":"35-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["Anti-trypanosomatid drug discovery: progress and challenges"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3519","authenticated-orcid":false,"given":"Manu","family":"De Rycker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-9284","authenticated-orcid":false,"given":"David","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-0130","authenticated-orcid":false,"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-1314","authenticated-orcid":false,"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"777_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","volume":"15","author":"MC Field","year":"2017","unstructured":"Field, M. C. et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat. Rev. Microbiol. 15, 217\u2013231 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"777_CR2","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3389\/fmicb.2016.02126","volume":"7","author":"A Ponte-Sucre","year":"2016","unstructured":"Ponte-Sucre, A. An overview of Trypanosoma brucei infections: an intense host-parasite interaction. Front. Microbiol. 7, 2126\u20132126 (2016).","journal-title":"Front. Microbiol."},{"key":"777_CR3","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","volume":"390","author":"P B\u00fcscher","year":"2017","unstructured":"B\u00fcscher, P., Cecchi, G., Jamonneau, V. & Priotto, G. Human African trypanosomiasis. Lancet 390, 2397\u20132409 (2017).","journal-title":"Lancet"},{"key":"777_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. Lancet 392, 951\u2013970 (2018).","journal-title":"Lancet"},{"key":"777_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.idc.2018.10.015","volume":"33","author":"LE Echeverria","year":"2019","unstructured":"Echeverria, L. E. & Morillo, C. A. American trypanosomiasis (Chagas disease). Infect. Dis. Clin. North. Am. 33, 119\u2013134 (2019).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"777_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","volume":"391","author":"JA P\u00e9rez-Molina","year":"2018","unstructured":"P\u00e9rez-Molina, J. A. & Molina, I. Chagas disease. Lancet 391, 82\u201394 (2018).","journal-title":"Lancet"},{"key":"777_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-pathol-020117-043711","volume":"14","author":"KM Bonney","year":"2019","unstructured":"Bonney, K. M., Luthringer, D. J., Kim, S. A., Garg, N. J. & Engman, D. M. Pathology and pathogenesis of Chagas heart disease. Annu. Rev. Pathol. 14, 421\u2013447 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"e999","DOI":"10.1016\/S2214-109X(21)00208-4","volume":"9","author":"V Kande Betu Ku Mesu","year":"2021","unstructured":"Kande Betu Ku Mesu, V. et al. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob. Health 9, e999\u2013e1008 (2021).","journal-title":"Lancet Glob. Health"},{"key":"777_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/tropicalmed5010029","volume":"5","author":"EA Dickie","year":"2020","unstructured":"Dickie, E. A. et al. New drugs for human African trypanosomiasis: a twenty first century success story. Trop. Med. Infect. Dis. 5, 29 (2020).","journal-title":"Trop. Med. Infect. Dis."},{"key":"777_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-018-0327-4","volume":"559","author":"M De Rycker","year":"2018","unstructured":"De Rycker, M., Baragana, B., Duce, S. L. & Gilbert, I. H. Challenges and recent progress in drug discovery for tropical diseases. Nature 559, 498\u2013506 (2018).","journal-title":"Nature"},{"key":"777_CR11","unstructured":"WHO. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021\u20132030 (WHO, 2020)."},{"key":"777_CR12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34039","volume":"7","author":"FJ Sanchez-Valdez","year":"2018","unstructured":"Sanchez-Valdez, F. J., Padilla, A., Wang, W., Orr, D. & Tarleton, R. L. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. eLife 7, e34039 (2018).","journal-title":"eLife"},{"key":"777_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41579-019-0238-x","volume":"17","author":"MP Barrett","year":"2019","unstructured":"Barrett, M. P., Kyle, D. E., Sibley, L. D., Radke, J. B. & Tarleton, R. L. Protozoan persister-like cells and drug treatment failure. Nat. Rev. Microbiol. 17, 607\u2013620 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"E801","DOI":"10.1073\/pnas.1619265114","volume":"114","author":"MA Mandell","year":"2017","unstructured":"Mandell, M. A. & Beverley, S. M. Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts. Proc. Natl Acad. Sci. USA 114, E801\u2013E810 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","volume":"244","author":"JW Bigger","year":"1944","unstructured":"Bigger, J. W. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244, 497\u2013500 (1944).","journal-title":"Lancet"},{"key":"777_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","volume":"15","author":"RA Fisher","year":"2017","unstructured":"Fisher, R. A., Gollan, B. & Helaine, S. Persistent bacterial infections and persister cells. Nat. Rev. Microbiol. 15, 453\u2013464 (2017).","journal-title":"Nat. Rev. Microbiol."},{"key":"777_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","volume":"17","author":"NQ Balaban","year":"2019","unstructured":"Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. Nat. Rev. Microbiol. 17, 441\u2013448 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"777_CR18","doi-asserted-by":"publisher","first-page":"606033","DOI":"10.3389\/fcimb.2020.606033","volume":"10","author":"A Voorberg-van der Wel","year":"2020","unstructured":"Voorberg-van der Wel, A., Kocken, C. H. M. & Zeeman, A. M. Modeling relapsing malaria: emerging technologies to study parasite-host interactions in the liver. Front. Cell Infect. Microbiol. 10, 606033 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"777_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/pathogens9030234","volume":"9","author":"A Cerutti","year":"2020","unstructured":"Cerutti, A., Blanchard, N. & Besteiro, S. The bradyzoite: a key developmental stage for the persistence and pathogenesis of toxoplasmosis. Pathogens 9, 234 (2020).","journal-title":"Pathogens"},{"key":"777_CR20","doi-asserted-by":"publisher","first-page":"200261","DOI":"10.1098\/rsob.200261","volume":"10","author":"AI Ward","year":"2020","unstructured":"Ward, A. I., Olmo, F., Atherton, R. L., Taylor, M. C. & Kelly, J. M. Trypanosoma cruzi amastigotes that persist in the colon during chronic stage murine infections have a reduced replication rate. Open Biol. 10, 200261 (2020).","journal-title":"Open Biol."},{"key":"777_CR21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"CA Morillo","year":"2015","unstructured":"Morillo, C. A. et al. Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy. N. Engl. J. Med. 373, 1295\u20131306 (2015).","journal-title":"N. Engl. J. Med."},{"key":"777_CR22","doi-asserted-by":"publisher","first-page":"106034","DOI":"10.1016\/j.actatropica.2021.106034","volume":"222","author":"Z D\u00edaz-Bello","year":"2021","unstructured":"D\u00edaz-Bello, Z. et al. Ten-year follow-up of the largest oral Chagas disease outbreak. Laboratory biomarkers of infection as indicators of therapeutic failure. Acta Trop. 222, 106034 (2021).","journal-title":"Acta Trop."},{"key":"777_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006612","volume":"12","author":"LM MacLean","year":"2018","unstructured":"MacLean, L. M. et al. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas\u2019 disease drug discovery. PLoS Negl. Trop. Dis. 12, e0006612 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR24","doi-asserted-by":"publisher","first-page":"e01242-20","DOI":"10.1128\/mBio.01242-20","volume":"11","author":"AI Ward","year":"2020","unstructured":"Ward, A. I. et al. In vivo analysis of Trypanosoma cruzi persistence foci at single-cell resolution. mBio 11, e01242-20 (2020).","journal-title":"mBio"},{"key":"777_CR25","doi-asserted-by":"publisher","first-page":"e00673-18","DOI":"10.1128\/mBio.00673-18","volume":"9","author":"PC Dumoulin","year":"2018","unstructured":"Dumoulin, P. C. & Burleigh, B. A. Stress-induced proliferation and cell cycle plasticity of intracellular Trypanosoma cruzi amastigotes. mBio 9, e00673-18 (2018).","journal-title":"mBio"},{"key":"777_CR26","doi-asserted-by":"publisher","first-page":"e00439-20","DOI":"10.1128\/AAC.00439-20","volume":"64","author":"MG \u00c1lvarez","year":"2020","unstructured":"\u00c1lvarez, M. G. et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: clinical, parasitological, and serological assessment after three years of follow-up. Antimicrob. Agents Chemother. 64, e00439-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR27","doi-asserted-by":"publisher","first-page":"eabb7656","DOI":"10.1126\/scitranslmed.abb7656","volume":"12","author":"JM Bustamante","year":"2020","unstructured":"Bustamante, J. M. et al. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci. Transl Med. 12, eabb7656 (2020).","journal-title":"Sci. Transl Med."},{"key":"777_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1099\/mic.0.000760","volume":"165","author":"S Mandal","year":"2019","unstructured":"Mandal, S., Njikan, S., Kumar, A., Early, J. V. & Parish, T. The relevance of persisters in tuberculosis drug discovery. Microbiology 165, 492\u2013499 (2019).","journal-title":"Microbiology"},{"key":"777_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008429","volume":"14","author":"V Goyal","year":"2020","unstructured":"Goyal, V. et al. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India. PLoS Negl. Trop. Dis. 14, e0008429 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijid.2018.07.008","volume":"74","author":"JW Gitari","year":"2018","unstructured":"Gitari, J. W. et al. Leishmaniasis recidivans by Leishmania tropica in Central Rift Valley region in Kenya. Int. J. Infect. Dis. 74, 109\u2013116 (2018).","journal-title":"Int. J. Infect. Dis."},{"key":"777_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004683","volume":"11","author":"J Kloehn","year":"2015","unstructured":"Kloehn, J., Saunders, E. C., O\u2019Callaghan, S., Dagley, M. J. & McConville, M. J. Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling. PLoS Pathog. 11, e1004683 (2015).","journal-title":"PLoS Pathog."},{"key":"777_CR32","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1128\/AAC.01781-15","volume":"60","author":"D Tegazzini","year":"2016","unstructured":"Tegazzini, D. et al. A replicative in vitro assay for drug discovery against Leishmania donovani. Antimicrob. Agents Chemother. 60, 3524\u20133532 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR33","first-page":"83","volume":"27","author":"SB Wolbach","year":"1912","unstructured":"Wolbach, S. B. & Binger, C. A. L. A contribution to the parasitology of trypanosomiasis. J. Med. Res. 27, 83\u2013107 (1912).","journal-title":"J. Med. Res."},{"key":"777_CR34","unstructured":"Peruzzi, M. in Final Report of the League of Nations International Commission on Human Trypanosomiasis 245\u2013328 (League of Nations International Commission, 1928)."},{"key":"777_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/030098587200900408","volume":"9","author":"BO Ikede","year":"1972","unstructured":"Ikede, B. O. & Losos, G. J. Pathology of the disease in sheep produced experimentally by Trypanosoma brucei. Vet. Pathol. 9, 278\u2013289 (1972).","journal-title":"Vet. Pathol."},{"key":"777_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.chom.2016.05.002","volume":"19","author":"S Trindade","year":"2016","unstructured":"Trindade, S. et al. Trypanosoma brucei parasites occupy and functionally adapt to the adipose tissue in mice. Cell Host Microbe 19, 837\u2013848 (2016).","journal-title":"Cell Host Microbe"},{"key":"777_CR37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.17716","volume":"5","author":"P Capewell","year":"2016","unstructured":"Capewell, P. et al. The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomes. eLife 5, e17716 (2016).","journal-title":"eLife"},{"key":"777_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cid\/ciaa897","volume":"73","author":"M Camara","year":"2021","unstructured":"Camara, M. et al. Extravascular dermal trypanosomes in suspected and confirmed cases of gambiense human African trypanosomiasis. Clin. Infect. Dis. 73, 12\u201320 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"777_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009866","volume":"17","author":"NP Crilly","year":"2021","unstructured":"Crilly, N. P. & Mugnier, M. R. Thinking outside the blood: perspectives on tissue-resident Trypanosoma brucei. PLoS Pathog. 17, e1009866 (2021).","journal-title":"PLoS Pathog."},{"key":"777_CR40","doi-asserted-by":"publisher","first-page":"109741","DOI":"10.1016\/j.celrep.2021.109741","volume":"36","author":"M De Niz","year":"2021","unstructured":"De Niz, M. et al. Organotypic endothelial adhesion molecules are key for Trypanosoma brucei tropism and virulence. Cell Rep. 36, 109741 (2021).","journal-title":"Cell Rep."},{"key":"777_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010060","volume":"17","author":"A Girard","year":"2021","unstructured":"Girard, A. et al. Raman spectroscopic analysis of skin as a diagnostic tool for human African trypanosomiasis. PLoS Pathog. 17, e1010060 (2021).","journal-title":"PLoS Pathog."},{"key":"777_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","volume":"7","author":"R Reithinger","year":"2007","unstructured":"Reithinger, R. et al. Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581\u2013596 (2007).","journal-title":"Lancet Infect. Dis."},{"key":"777_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijpddr.2019.06.003","volume":"11","author":"D Caridha","year":"2019","unstructured":"Caridha, D. et al. Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. Int. J. Parasitol. Drugs Drug Resist. 11, 106\u2013117 (2019).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"777_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","volume":"10","author":"D Steverding","year":"2017","unstructured":"Steverding, D. The history of leishmaniasis. Parasit. Vectors 10, 82 (2017).","journal-title":"Parasit. Vectors"},{"key":"777_CR45","first-page":"147","volume":"1","author":"HE Meleney","year":"1925","unstructured":"Meleney, H. E. The histopathology of kala-azar in the hamster, monkey and man. Am. J. Pathol. 1, 147\u2013168 (1925).","journal-title":"Am. J. Pathol."},{"key":"777_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1021\/acsinfecdis.0c00864","volume":"7","author":"B Dom\u00ednguez-Asenjo","year":"2021","unstructured":"Dom\u00ednguez-Asenjo, B. et al. Bioluminescent imaging identifies thymus, as overlooked colonized organ, in a chronic model of Leishmania donovani mouse visceral leishmaniasis. ACS Infect. Dis. 7, 871\u2013883 (2021).","journal-title":"ACS Infect. Dis."},{"key":"777_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1128\/jcm.18.2.327-330.1983","volume":"18","author":"H Feilij","year":"1983","unstructured":"Feilij, H., Muller, L. & Cappa, S. M. G. Direct micromethod for diagnosis of acute and congenital Chagas\u2019 disease. J. Clin. Microbiol. 18, 327\u2013330 (1983).","journal-title":"J. Clin. Microbiol."},{"key":"777_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.anndiagpath.2009.06.008","volume":"14","author":"AE Silva","year":"2010","unstructured":"Silva, A. E. et al. Acute Chagas\u2019 disease in postrenal transplant and treatment with benzonidazole. Ann. Diagn. Pathol. 14, 199\u2013203 (2010).","journal-title":"Ann. Diagn. Pathol."},{"key":"777_CR49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.pt.2016.08.009","volume":"32","author":"MD Lewis","year":"2016","unstructured":"Lewis, M. D. & Kelly, J. M. Putting infection dynamics at the heart of Chagas disease. Trends Parasitol. 32, 899\u2013911 (2016).","journal-title":"Trends Parasitol."},{"key":"777_CR50","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/cmi.12297","volume":"16","author":"MD Lewis","year":"2014","unstructured":"Lewis, M. D. et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell. Microbiol. 16, 1285\u20131300 (2014).","journal-title":"Cell. Microbiol."},{"key":"777_CR51","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1021\/acsinfecdis.1c00118","volume":"7","author":"S Wittlin","year":"2021","unstructured":"Wittlin, S. & M\u00e4ser, P. From magic bullet to magic bomb: reductive bioactivation of antiparasitic agents. ACS Infect. Dis. 7, 2777\u20132786 (2021).","journal-title":"ACS Infect. Dis."},{"key":"777_CR52","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1073\/pnas.1807915115","volume":"115","author":"RJ Wall","year":"2018","unstructured":"Wall, R. J. et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc. Natl Acad. Sci. USA 115, 9616\u20139621 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","volume":"560","author":"S Wyllie","year":"2018","unstructured":"Wyllie, S. et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 560, 192\u2013197 (2018).","journal-title":"Nature"},{"key":"777_CR54","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1073\/pnas.1820175116","volume":"116","author":"S Wyllie","year":"2019","unstructured":"Wyllie, S. et al. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc. Natl Acad. Sci. USA 116, 9318\u20139323 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR55","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1021\/acs.jmedchem.1c00047","volume":"64","author":"M Thomas","year":"2021","unstructured":"Thomas, M. et al. Scaffold-hopping strategy on a series of proteasome inhibitors led to a preclinical candidate for the treatment of visceral leishmaniasis. J. Med. Chem. 64, 5905\u20135930 (2021).","journal-title":"J. Med. Chem."},{"key":"777_CR56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","volume":"537","author":"S Khare","year":"2016","unstructured":"Khare, S. et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 537, 229\u2013233 (2016).","journal-title":"Nature"},{"key":"777_CR57","doi-asserted-by":"publisher","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","volume":"64","author":"CE Mowbray","year":"2021","unstructured":"Mowbray, C. E. et al. DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis. J. Med. Chem. 64, 16159\u201316176 (2021).","journal-title":"J. Med. Chem."},{"key":"777_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpddr.2018.01.006","volume":"8","author":"M Van den Kerkhof","year":"2018","unstructured":"Van den Kerkhof, M. et al. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. Int. J. Parasitol. Drugs Drug Resist. 8, 81\u201386 (2018).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"777_CR59","doi-asserted-by":"publisher","first-page":"e00829-19","DOI":"10.1128\/AAC.00829-19","volume":"63","author":"GJ Wijnant","year":"2019","unstructured":"Wijnant, G. J. et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis. Antimicrob. Agents Chemother. 63, e00829-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR60","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1473-3099(20)30844-6","volume":"21","author":"F Torrico","year":"2021","unstructured":"Torrico, F. et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect. Dis. 21, 1129\u20131140 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"777_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4226-2","volume":"21","author":"D Molina-Morant","year":"2020","unstructured":"Molina-Morant, D. et al. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized phase II non-inferiority clinical trial. Trials 21, 328 (2020).","journal-title":"Trials"},{"key":"777_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"777_CR63","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","volume":"63","author":"A Nagle","year":"2020","unstructured":"Nagle, A. et al. Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases. J. Med. Chem. 63, 10773\u201310781 (2020).","journal-title":"J. Med. Chem."},{"key":"777_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01664-4","volume":"8","author":"M Shalev-Benami","year":"2017","unstructured":"Shalev-Benami, M. et al. Atomic resolution snapshot of Leishmania ribosome inhibition by the aminoglycoside paromomycin. Nat. Commun. 8, 1589 (2017).","journal-title":"Nat. Commun."},{"key":"777_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004014","volume":"9","author":"J Riley","year":"2015","unstructured":"Riley, J. et al. Development of a fluorescence-based Trypanosoma cruzi CYP51 inhibition assay for effective compound triaging in drug discovery programmes for Chagas disease. PLoS Negl. Trop. Dis. 9, e0004014 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR66","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1021\/acsinfecdis.9b00426","volume":"6","author":"RJ Wall","year":"2020","unstructured":"Wall, R. J. et al. The Qi site of cytochrome b is a promiscuous drug target in Trypanosoma cruzi and Leishmania donovani. ACS Infect. Dis. 6, 515\u2013528 (2020).","journal-title":"ACS Infect. Dis."},{"key":"777_CR67","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","volume":"370","author":"I Molina","year":"2014","unstructured":"Molina, I. et al. Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease. N. Engl. J. Med. 370, 1899\u20131908 (2014).","journal-title":"N. Engl. J. Med."},{"key":"777_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","volume":"18","author":"F Torrico","year":"2018","unstructured":"Torrico, F. et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect. Dis. 18, 419\u2013430 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"777_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001736","volume":"6","author":"SS Gunatilleke","year":"2012","unstructured":"Gunatilleke, S. S. et al. Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl. Trop. Dis. 6, e1736 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1021\/acsinfecdis.8b00226","volume":"5","author":"V Corpas-Lopez","year":"2019","unstructured":"Corpas-Lopez, V. et al. Pharmacological validation of N-myristoyltransferase as a drug target in Leishmania donovani. ACS Infect. Dis. 5, 111\u2013122 (2019).","journal-title":"ACS Infect. Dis."},{"key":"777_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1021\/jm201091t","volume":"55","author":"S Brand","year":"2012","unstructured":"Brand, S. et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J. Med. Chem. 55, 140\u2013152 (2012).","journal-title":"J. Med. Chem."},{"key":"777_CR72","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1073\/pnas.70.3.782","volume":"70","author":"BN Ames","year":"1973","unstructured":"Ames, B. N., Lee, F. D. & Durston, W. E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl Acad. Sci. USA 70, 782\u2013786 (1973).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR73","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","volume":"31","author":"BN Ames","year":"1975","unstructured":"Ames, B. N., McCann, J. & Yamasaki, E. Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test. Mutat. Res. 31, 347\u2013364 (1975).","journal-title":"Mutat. Res."},{"key":"777_CR74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/AAC.00887-13","volume":"58","author":"AG Peniche","year":"2014","unstructured":"Peniche, A. G. et al. Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major. Antimicrob. Agents Chemother. 58, 78\u201387 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR75","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1021\/acsinfecdis.1c00139","volume":"7","author":"B Dom\u00ednguez-Asenjo","year":"2021","unstructured":"Dom\u00ednguez-Asenjo, B. et al. Ex vivo phenotypic screening of two small repurposing drug collections identifies nifuratel as a potential new treatment against visceral and cutaneous leishmaniasis. ACS Infect. Dis. 7, 2390\u20132401 (2021).","journal-title":"ACS Infect. Dis."},{"key":"777_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.micinf.2018.03.002","volume":"20","author":"L da Silva Lara","year":"2018","unstructured":"da Silva Lara, L. et al. Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease. Microbes Infect. 20, 312\u2013316 (2018).","journal-title":"Microbes Infect."},{"key":"777_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001932","volume":"6","author":"M De Rycker","year":"2012","unstructured":"De Rycker, M. et al. A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl. Trop. Dis. 6, e1932 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004094","volume":"9","author":"A Nuhs","year":"2015","unstructured":"Nuhs, A. et al. Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity. PLoS Negl. Trop. Dis. 9, e0004094 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ejps.2018.06.002","volume":"121","author":"MD Jim\u00e9nez-Ant\u00f3n","year":"2018","unstructured":"Jim\u00e9nez-Ant\u00f3n, M. D. et al. Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum. Eur. J. Pharm. Sci. 121, 281\u2013286 (2018).","journal-title":"Eur. J. Pharm. Sci."},{"key":"777_CR80","doi-asserted-by":"publisher","first-page":"e00497-17","DOI":"10.1128\/AAC.00497-17","volume":"61","author":"AA Voak","year":"2017","unstructured":"Voak, A. A., Harris, A., Qaiser, Z., Croft, S. L. & Seifert, K. Pharmacodynamics and biodistribution of single-dose liposomal amphotericin B at different stages of experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 61, e00497-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR81","doi-asserted-by":"publisher","first-page":"e02419-17","DOI":"10.1128\/AAC.02419-17","volume":"62","author":"K Van Bocxlaer","year":"2018","unstructured":"Van Bocxlaer, K. et al. Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles. Antimicrob. Agents Chemother. 62, e02419-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR82","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/jac\/dkw012","volume":"71","author":"K Van Bocxlaer","year":"2016","unstructured":"Van Bocxlaer, K., Yardley, V., Murdan, S. & Croft, S. L. Drug permeation and barrier damage in Leishmania-infected mouse skin. J. Antimicrob. Chemother. 71, 1578\u20131585 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"777_CR83","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/jphp.12548","volume":"68","author":"K Van Bocxlaer","year":"2016","unstructured":"Van Bocxlaer, K., Yardley, V., Murdan, S. & Croft, S. L. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB\/c mouse model. J. Pharm. Pharmacol. 68, 862\u2013872 (2016).","journal-title":"J. Pharm. Pharmacol."},{"key":"777_CR84","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","volume":"34","author":"AH Fairlamb","year":"2018","unstructured":"Fairlamb, A. H. & Horn, D. Melarsoprol resistance in African trypanosomiasis. Trends Parasitol. 34, 481\u2013492 (2018).","journal-title":"Trends Parasitol."},{"key":"777_CR85","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/361173a0","volume":"361","author":"NS Carter","year":"1993","unstructured":"Carter, N. S. & Fairlamb, A. H. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361, 173\u2013176 (1993).","journal-title":"Nature"},{"key":"777_CR86","doi-asserted-by":"publisher","first-page":"828111","DOI":"10.3389\/fvets.2022.828111","volume":"9","author":"KI Kasozi","year":"2022","unstructured":"Kasozi, K. I., MacLeod, E. T., Ntulume, I. & Welburn, S. C. An update on African trypanocide pharmaceutics and resistance. Front. Vet. Sci. 9, 828111 (2022).","journal-title":"Front. Vet. Sci."},{"key":"777_CR87","doi-asserted-by":"publisher","first-page":"10996","DOI":"10.1073\/pnas.1202885109","volume":"109","author":"N Baker","year":"2012","unstructured":"Baker, N. et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc. Natl Acad. Sci. USA 109, 10996\u201311001 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","volume":"5","author":"FE Graf","year":"2015","unstructured":"Graf, F. E. et al. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates. Int. J. Parasitol. Drugs Drug Resist. 5, 65\u201368 (2015).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"777_CR89","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/cid\/ciaa1236","volume":"72","author":"JE Potvin","year":"2021","unstructured":"Potvin, J. E., Leprohon, P., Queffeulou, M., Sundar, S. & Ouellette, M. Mutations in an aquaglyceroporin as a proven marker of antimony clinical resistance in the parasite Leishmania donovani. Clin. Infect. Dis. 72, e526\u2013e532 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"777_CR90","doi-asserted-by":"publisher","first-page":"19932","DOI":"10.1073\/pnas.1311535110","volume":"110","author":"MR Perry","year":"2013","unstructured":"Perry, M. R., Wyllie, S., Raab, A., Feldmann, J. & Fairlamb, A. H. Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis. Proc. Natl Acad. Sci. USA 110, 19932\u201319937 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR91","doi-asserted-by":"crossref","unstructured":"Gamarro, F., S\u00e1nchez-Ca\u00f1ete, M. P. & Castanys, S. in Drug Resistance in Leishmania Parasites: Consequences, Molecular Mechanisms and Possible Treatments (eds Ponte-Sucre, A., Diaz, E. & Padr\u00f3n-Nieves, M.) 351\u2013379 (Springer, 2013).","DOI":"10.1007\/978-3-7091-1125-3_17"},{"key":"777_CR92","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00281-020-00796-y","volume":"42","author":"J Alvar","year":"2020","unstructured":"Alvar, J. et al. Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. Semin. Immunopathol. 42, 231\u2013246 (2020).","journal-title":"Semin. Immunopathol."},{"key":"777_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000105","volume":"17","author":"P Capewell","year":"2019","unstructured":"Capewell, P. et al. Resolving the apparent transmission paradox of African sleeping sickness. PLoS Biol. 17, e3000105 (2019).","journal-title":"PLoS Biol."},{"key":"777_CR94","volume":"21","author":"M De Niz","year":"2019","unstructured":"De Niz, M. et al. Intravital imaging of host-parasite interactions in skin and adipose tissues. Cell Microbiol. 21, e13023 (2019).","journal-title":"Cell Microbiol."},{"key":"777_CR95","first-page":"257","volume":"6","author":"JR Franco","year":"2014","unstructured":"Franco, J. R., Simarro, P. P., Diarra, A. & Jannin, J. G. Epidemiology of human African trypanosomiasis. Clin. Epidemiol. 6, 257\u2013275 (2014).","journal-title":"Clin. Epidemiol."},{"key":"777_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008261","volume":"14","author":"JR Franco","year":"2020","unstructured":"Franco, J. R. et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018. PLoS Negl. Trop. Dis. 14, e0008261 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR97","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/microorganisms9051101","volume":"9","author":"I Azami-Conesa","year":"2021","unstructured":"Azami-Conesa, I., Gomez-Munoz, M. T. & Martinez-Diaz, R. A. A systematic review (1990\u20132021) of wild animals infected with zoonotic Leishmania. Microorganisms 9, 1101 (2021).","journal-title":"Microorganisms"},{"key":"777_CR98","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ijpara.2005.07.001","volume":"35","author":"M Gramiccia","year":"2005","unstructured":"Gramiccia, M. & Gradoni, L. The current status of zoonotic leishmaniases and approaches to disease control. Int. J. Parasitol. 35, 1169\u20131180 (2005).","journal-title":"Int. J. Parasitol."},{"key":"777_CR99","doi-asserted-by":"publisher","DOI":"10.1111\/tbed.14061","author":"AK Kushwaha","year":"2021","unstructured":"Kushwaha, A. K. et al. Domestic mammals as reservoirs for Leishmania donovani on the Indian subcontinent: possibility and consequences on elimination. Transbound. Emerg. Dis. https:\/\/doi.org\/10.1111\/tbed.14061 (2021).","journal-title":"Transbound. Emerg. Dis."},{"key":"777_CR100","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13071-019-3541-5","volume":"12","author":"E Rodr\u00edguez-Mongu\u00ed","year":"2019","unstructured":"Rodr\u00edguez-Mongu\u00ed, E., Cantillo-Barraza, O., Prieto-Alvarado, F. E. & Cucunub\u00e1, Z. M. Heterogeneity of Trypanosoma cruzi infection rates in vectors and animal reservoirs in Colombia: a systematic review and meta-analysis. Parasit. Vectors 12, 308 (2019).","journal-title":"Parasit. Vectors"},{"key":"777_CR101","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13071-018-3067-2","volume":"11","author":"AM Jansen","year":"2018","unstructured":"Jansen, A. M., Xavier, S. C. & Roque, A. L. R. Trypanosoma cruzi transmission in the wild and its most important reservoir hosts in Brazil. Parasit. Vectors 11, 502 (2018).","journal-title":"Parasit. Vectors"},{"key":"777_CR102","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/pathogens10091148","volume":"10","author":"JM Austen","year":"2021","unstructured":"Austen, J. M. & Barbosa, A. D. Diversity and epidemiology of bat trypanosomes: a one health perspective. Pathogens 10, 1148 (2021).","journal-title":"Pathogens"},{"key":"777_CR103","first-page":"447","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard, A. Parsing clinical success rates. Nat. Rev. Drug Discov. 15, 447 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"777_CR104","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"777_CR105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-021-03597-x","volume":"595","author":"D Autheman","year":"2021","unstructured":"Autheman, D. et al. An invariant Trypanosoma vivax vaccine antigen induces protective immunity. Nature 595, 96\u2013100 (2021).","journal-title":"Nature"},{"key":"777_CR106","unstructured":"Romero-Ramirez, A. I. Antigen discovery in Trypanosoma vivax. Thesis, Univ. Liverpool https:\/\/livrepository.liverpool.ac.uk\/3088027\/1\/201193495_Feb2020.pdf (2020)."},{"key":"777_CR107","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/14760584.2021.1990043","volume":"20","author":"PM Kaye","year":"2021","unstructured":"Kaye, P. M. et al. Overcoming roadblocks in the development of vaccines for leishmaniasis. Expert Rev. Vaccines 20, 1419\u20131430 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"777_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005527","volume":"11","author":"M Osman","year":"2017","unstructured":"Osman, M. et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl. Trop. Dis. 11, e0005527 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17154-z","volume":"11","author":"WW Zhang","year":"2020","unstructured":"Zhang, W. W. et al. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat. Commun. 11, 3461 (2020).","journal-title":"Nat. Commun."},{"key":"777_CR110","doi-asserted-by":"publisher","first-page":"119390","DOI":"10.1016\/j.ijpharm.2020.119390","volume":"586","author":"JS Lanza","year":"2020","unstructured":"Lanza, J. S. et al. A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. Int. J. Pharm. 586, 119390 (2020).","journal-title":"Int. J. Pharm."},{"key":"777_CR111","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.vaccine.2018.02.111","volume":"36","author":"J Fern\u00e1ndez Cotrina","year":"2018","unstructured":"Fern\u00e1ndez Cotrina, J. et al. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend\u00ae against canine leishmaniosis. Vaccine 36, 1972\u20131982 (2018).","journal-title":"Vaccine"},{"key":"777_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20569-3","volume":"12","author":"H Ashwin","year":"2021","unstructured":"Ashwin, H. et al. Characterization of a new Leishmania major strain for use in a controlled human infection model. Nat. Commun. 12, 215 (2021).","journal-title":"Nat. Commun."},{"key":"777_CR113","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","volume":"16","author":"A Zumla","year":"2016","unstructured":"Zumla, A. et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect. Dis. 16, e47\u2013e63 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"777_CR114","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.3389\/fmicb.2018.02655","volume":"9","author":"S Varikuti","year":"2018","unstructured":"Varikuti, S. et al. Host-directed drug therapies for neglected tropical diseases caused by protozoan parasites. Front. Microbiol. 9, 2655 (2018).","journal-title":"Front. Microbiol."},{"key":"777_CR115","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1021\/acsinfecdis.8b00298","volume":"5","author":"SPS Rao","year":"2019","unstructured":"Rao, S. P. S. et al. Drug discovery for kinetoplastid diseases: future directions. ACS Infect. Dis. 5, 152\u2013157 (2019).","journal-title":"ACS Infect. Dis."},{"key":"777_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005480","volume":"11","author":"S Lamotte","year":"2017","unstructured":"Lamotte, S., Sp\u00e4th, G. F., Rachidi, N. & Prina, E. The enemy within: targeting host-parasite interaction for antileishmanial drug discovery. PLoS Negl. Trop. Dis. 11, e0005480 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008050","volume":"14","author":"SG Thacker","year":"2020","unstructured":"Thacker, S. G. et al. CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 14, e0008050 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR118","unstructured":"Drugs for Neglected Diseases initiative. CpG-D35 for cutaneous leishmaniasis. DNDi https:\/\/dndi.org\/research-development\/portfolio\/cpg-d35\/ (2022)."},{"key":"777_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000491","volume":"3","author":"C Miranda-Verastegui","year":"2009","unstructured":"Miranda-Verastegui, C. et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3, e491 (2009).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR120","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/tropicalmed2030036","volume":"2","author":"AK Mitra","year":"2017","unstructured":"Mitra, A. K. & Mawson, A. R. Neglected tropical diseases: epidemiology and global burden. Trop. Med. Infect. Dis. 2, 36 (2017).","journal-title":"Trop. Med. Infect. Dis."},{"key":"777_CR121","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1128\/AAC.00520-15","volume":"59","author":"AF Francisco","year":"2015","unstructured":"Francisco, A. F. et al. Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob. Agents Chemother. 59, 4653\u20134661 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR122","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.chembiol.2021.02.008","volume":"28","author":"LS Paradela","year":"2021","unstructured":"Paradela, L. S. et al. Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial. Cell Chem. Biol. 28, 711\u2013721.e8 (2021).","journal-title":"Cell Chem. Biol."},{"key":"777_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005971","volume":"12","author":"S Wyllie","year":"2016","unstructured":"Wyllie, S. et al. Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in. Leishmania. PLoS Pathog. 12, e1005971 (2016).","journal-title":"Leishmania. PLoS Pathog."},{"key":"777_CR124","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41564-020-0745-6","volume":"5","author":"M Saldivia","year":"2020","unstructured":"Saldivia, M. et al. Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. Nat. Microbiol. 5, 1207\u20131216 (2020).","journal-title":"Nat. Microbiol."},{"key":"777_CR125","doi-asserted-by":"publisher","first-page":"e00235-18","DOI":"10.1128\/AAC.00235-18","volume":"62","author":"RJ Wall","year":"2018","unstructured":"Wall, R. J. et al. Antitrypanosomal 8-hydroxy-naphthyridines are chelators of divalent transition metals. Antimicrob. Agents Chemother. 62, e00235-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pt.2021.09.002","volume":"38","author":"D Horn","year":"2022","unstructured":"Horn, D. Genome-scale RNAi screens in African trypanosomes. Trends Parasitol. 38, 160\u2013173 (2022).","journal-title":"Trends Parasitol."},{"key":"777_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008932","volume":"16","author":"F Giordani","year":"2020","unstructured":"Giordani, F. et al. Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathog. 16, e1008932 (2020).","journal-title":"PLoS Pathog."},{"key":"777_CR128","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijpddr.2018.03.004","volume":"8","author":"C Fernandez-Prada","year":"2018","unstructured":"Fernandez-Prada, C. et al. High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. Int. J. Parasitol. Drugs Drug Resist. 8, 165\u2013173 (2018).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"777_CR129","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/acsinfecdis.7b00244","volume":"4","author":"NG Jones","year":"2018","unstructured":"Jones, N. G., Catta-Preta, C. M. C., Lima, A. & Mottram, J. C. Genetically validated drug targets in Leishmania: current knowledge and future prospects. ACS Infect. Dis. 4, 467\u2013477 (2018).","journal-title":"ACS Infect. Dis."},{"key":"777_CR130","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01535-21","volume":"66","author":"M Lima","year":"2021","unstructured":"Lima, M. et al. Identification of a proteasome-targeting arylsulfonamide with potential for the treatment of Chagas\u2019 disease. Antimicrob. Agents Chemother. 66, e0153521 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"777_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac319","author":"S Altmann","year":"2022","unstructured":"Altmann, S. et al. Oligo targeting for profiling drug resistance mutations in the parasitic trypanosomatids. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkac319 (2022).","journal-title":"Nucleic Acids Res."},{"key":"777_CR132","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","volume":"69","author":"CA Morillo","year":"2017","unstructured":"Morillo, C. A. et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J. Am. Coll. Cardiol. 69, 939\u2013947 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"777_CR133","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17460441.2020.1806233","volume":"15","author":"E Chatelain","year":"2020","unstructured":"Chatelain, E. & Scandale, I. Animal models of Chagas disease and their translational value to drug development. Expert Opin. Drug Discov. 15, 1381\u20131402 (2020).","journal-title":"Expert Opin. Drug Discov."},{"key":"777_CR134","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1073\/pnas.94.8.4167","volume":"94","author":"PG Kennedy","year":"1997","unstructured":"Kennedy, P. G. et al. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc. Natl Acad. Sci. USA 94, 4167\u20134170 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"777_CR135","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1383-5769(02)00044-2","volume":"51","author":"FW Jennings","year":"2002","unstructured":"Jennings, F. W. et al. Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol. Int. 51, 381\u2013388 (2002).","journal-title":"Parasitol. Int."},{"key":"777_CR136","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/jac\/dku393","volume":"70","author":"H Burrell-Saward","year":"2015","unstructured":"Burrell-Saward, H., Rodgers, J., Bradley, B., Croft, S. L. & Ward, T. H. A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis. J. Antimicrob. Chemother. 70, 510\u2013517 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"777_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0036-46652014000100001","volume":"56","author":"EN Lor\u00eda-Cervera","year":"2014","unstructured":"Lor\u00eda-Cervera, E. N. & Andrade-Narv\u00e1ez, F. J. Animal models for the study of leishmaniasis immunology. Rev. Inst. Med. Trop. Sao Paulo 56, 1\u201311 (2014).","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"777_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55474-3","volume":"9","author":"D Mendes Costa","year":"2019","unstructured":"Mendes Costa, D., Cec\u00edlio, P., Santar\u00e9m, N., Cordeiro-da-Silva, A. & Tavares, J. Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery. Sci. Rep. 9, 18989 (2019).","journal-title":"Sci. Rep."},{"key":"777_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61662-3","volume":"10","author":"HB Ong","year":"2020","unstructured":"Ong, H. B., Clare, S., Roberts, A. J., Wilson, M. E. & Wright, G. J. Establishment, optimisation and quantitation of a bioluminescent murine infection model of visceral leishmaniasis for systematic vaccine screening. Sci. Rep. 10, 4689 (2020).","journal-title":"Sci. Rep."},{"key":"777_CR140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003889","volume":"9","author":"ER Mears","year":"2015","unstructured":"Mears, E. R., Modabber, F., Don, R. & Johnson, G. E. A review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 9, e0003889 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"777_CR141","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.2147\/DDDT.S90208","volume":"9","author":"E Chatelain","year":"2015","unstructured":"Chatelain, E. & Konar, N. Translational challenges of animal models in Chagas disease drug development: a review. Drug Des. Devel. Ther. 9, 4807\u20134823 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"777_CR142","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3390\/molecules25122799","volume":"25","author":"AF Francisco","year":"2020","unstructured":"Francisco, A. F. et al. Challenges in Chagas disease drug development. Molecules 25, 2799 (2020).","journal-title":"Molecules"},{"key":"777_CR143","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1021\/acsinfecdis.0c00061","volume":"6","author":"EV Ayala","year":"2020","unstructured":"Ayala, E. V. et al. C57BL\/6 \u03b1-1,3-galactosyltransferase knockout mouse as an animal model for experimental Chagas disease. ACS Infect. Dis. 6, 1807\u20131815 (2020).","journal-title":"ACS Infect. Dis."},{"key":"777_CR144","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1124\/dmd.119.086397","volume":"47","author":"CJ Henderson","year":"2019","unstructured":"Henderson, C. J. et al. An extensively humanized mouse model to predict pathways of drug disposition and drug\/drug interactions, and to facilitate design of clinical trials. Drug Metab. Dispos. 47, 601\u2013615 (2019).","journal-title":"Drug Metab. Dispos."},{"key":"777_CR145","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-3024.2011.01293.x","volume":"33","author":"S Magez","year":"2011","unstructured":"Magez, S. & Caljon, G. Mouse models for pathogenic African trypanosomes: unravelling the immunology of host-parasite-vector interactions. Parasite Immunol. 33, 423\u2013429 (2011).","journal-title":"Parasite Immunol."},{"key":"777_CR146","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pt.2008.05.010","volume":"24","author":"N Antoine-Moussiaux","year":"2008","unstructured":"Antoine-Moussiaux, N., Magez, S. & Desmecht, D. Contributions of experimental mouse models to the understanding of African trypanosomiasis. Trends Parasitol. 24, 411\u2013418 (2008).","journal-title":"Trends Parasitol."}],"updated-by":[{"DOI":"10.1038\/s41579-022-00797-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000}}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00777-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:34:25Z","timestamp":1733938465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-022-00777-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1038\/s41579-022-00777-y","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"13 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41579-022-00797-8","URL":"https:\/\/doi.org\/10.1038\/s41579-022-00797-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}